Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

United Health Products (UEEC) Research & Development (2018 - 2025)

United Health Products (UEEC) has disclosed Research & Development for 8 consecutive years, with $25334.0 as the latest value for Q3 2025.

  • On a quarterly basis, Research & Development fell 61.55% to $25334.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $331347.0, a 17.25% decrease, with the full-year FY2024 number at $355936.0, down 40.56% from a year prior.
  • Research & Development was $25334.0 for Q3 2025 at United Health Products, down from $80983.0 in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $218676.0 in Q1 2023 to a low of $19757.0 in Q3 2021.
  • A 5-year average of $107333.4 and a median of $105113.0 in 2023 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: crashed 67.09% in 2021, then surged 988.11% in 2022.
  • United Health Products' Research & Development stood at $90636.0 in 2021, then skyrocketed by 131.28% to $209620.0 in 2022, then decreased by 26.89% to $153260.0 in 2023, then fell by 29.02% to $108779.0 in 2024, then crashed by 76.71% to $25334.0 in 2025.
  • Per Business Quant, the three most recent readings for UEEC's Research & Development are $25334.0 (Q3 2025), $80983.0 (Q2 2025), and $116251.0 (Q1 2025).